APA (7th ed.) Citation

M, D., J, V., V, C., I, V., J, H., FP, D., . . . M, K. (2021). Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(8), 1097. https://doi.org/10.2967/jnumed.120.255679

Chicago Style (17th ed.) Citation

M, D'Huyvetter, et al. "Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 62, no. 8 (2021): 1097. https://doi.org/10.2967/jnumed.120.255679.

MLA (9th ed.) Citation

M, D'Huyvetter, et al. "Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 62, no. 8, 2021, p. 1097, https://doi.org/10.2967/jnumed.120.255679.